PTAB deals Bass another blow
21-10-2015
Bass set for first IPR trial as Shire petition proceeds
09-10-2015
Bass targets the University of Pennsylvania in IPR petitions
01-09-2015
PTAB shoots down Kyle Bass IPR request
25-08-2015
Dacian G / Shutterstock.com
Hedge fund manager Kyle Bass’s Coalition for Affordable Drugs has suffered another setback in its bid to knock out allegedly spurious patents after the US Patent and Trademark Office (USPTO) declined to institute an inter partes review (IPR) of a patent owned by Biogen.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Kyle Bass; Coalition for Affordable Drugs; PTAB; USPTO; Biogen; Tecfidera; MS
